You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Translation of Interferometric-based Free-solution Assay Methodology

    SBC: MERU BIOTECHNOLOGIES            Topic: 300

    Project Summary: Lung cancer is the leading cause of cancer-related deaths in the United States. Low dose chest computed tomography (CT) screening programs that target high-risk individuals can reduce lung cancer-specific mortality by 20% and overall mortality by 6.9%. There is a growing movement to implement this life saving screening into routine practice, with endorsements from the U.S. Prevent ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Trans‐nasal delivery of chemotherapy to glioblastoma using magnetic nanoparticles and magnetic focusing

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: 102

    Abstract Glioblastoma multiforme GBM is the deadliest form of brain tumor The current treatment includes a combination of surgical resection chemotherapy radiation and electrical disruption of mitosis has only extended survival to approximately to years Preliminary pre clinical findings suggest the potential effectiveness of the candidate drug cyclopamine However the drug is toxic to ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Treating collagen induced arthritis CIA with immunoregulatory nanoparticles

    SBC: LeukoSight Inc            Topic: NIAMS

    DESCRIPTION provided by applicant The title of this project is andquot Treating Collagen induced Arthritis with Fc Receptor Activating Nanoparticlesandquot We and others have identified and characterized a population of macrophages with potent immunorergulatory activity The goal of the present proposal is to induce the production of regulatory macrophages R M in mice and determine wheth ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Treating EAE disease with Fc-Dimers

    SBC: LeukoSight Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): We have developed a recombinant polypeptide that we have termed Fc-Dimers (Di -mers). This product has potent anti-inflammatory activity in vitro, and we propose to test this reagent in an animal model of autoimmunedisease. We have selected the murine disease, Experimental Autoimmune Encephalomyelitis (EAE), a model for human multiple sclerosis (MS). Pathol ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Treatment of diabetic retinopathy with TrkB agonist antibodies

    SBC: ZEBRA BIOLOGICS INC            Topic: NEI

    Project Summary/AbstractDiabetic retinopathy (DR) is a major co-morbidity for patients with Type 1 and Type 2 diabetes. The incidence and severity of DR increase with duration of diabetes and approximately 30 percent will experience vision-threatening deficits. Work over the past decade has shown that the neural deficits observed in DR occur early in the natural history of the disease and likely p ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Treatment of Gastroparesis with Multi-Channel Pacing

    SBC: Gi Stimulation, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this project is to investigate the safety and efficacy of multi-channel gastric electrical stimulation (MGS) in the treatment of patients with diabetic gastroparesis refractory to standard medical therapy. Previous animal studies have shown that appropriate multi-channel electrical stimulation of the stomach will: a) entrain gastric myoelectrical a ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. TREATMENT OF OVARIAN CANCER WITH CONTORTROSTATIN

    SBC: PIVOTAL BIOSCIENCES            Topic: N/A

    DESCRIPTION: (Applicant's Description) Ovarian carcinoma (OC) is the fourth most frequent form of cancer death of women in the United States. Approximately 1 in 70 women in the US will develop OC; in advanced stages of the disease there is a 5-year survival of about 15-20%. Present methods of treatment for advanced sta ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  8. Triagonist Peptide Therapeutics for Neuroprotection

    SBC: VELUM INC            Topic: 300

    Project Summary Morbidity associated with neuronal degeneration and dysfunction poses an increasing public health burden. Among the wide range of etiologies that result in neuronal dysfunction, including chronic conditions such as Alzheimer’s and Parkinson’s disease and vascular dementias, one major cause that has been largely unnoticed but is increasingly recognized as a major concern is trau ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Tribosupplementation of Injured Joints

    SBC: TRIBOLOGICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Injury is a well established risk factor in the pathogenesis of osteoarthritis (OA) as supported by several large longitudinal population studies. Patients with meniscal and ACL injuries in particular are at risk for early OA. Chondroprotection of the joint surface is mediated by lubricin which forms an ordered nanofilm and provides anti-adhesion via steric rep ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Tribosupplementation of Injured Joints

    SBC: TRIBOLOGICS, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Joint injury is a well established risk factor in the pathogenesis of post-traumatic osteoarthritis (PTOA). In particular, patients with meniscal tears are at high risk for early PTOA. Chondroprotection of the joint surface is mediated by lubricin, a large glycoprotien which forms a lubricating nanofilm on the cartilage surface and provides anti-adhesion via st ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government